Overview

Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of fixed combination of valsartan (40 mg and 80 mg) and amlodipine (2.5 mg and 5 mg), valsartan and amlodipine alone, and placebo in reducing blood pressure. The study will investigate the dose response relationship for the combinations, monotherapies, and placebo.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Amlodipine
Valsartan